These results demonstrate that the antiproliferative effect of AdoMet in CRC cells is independent of p53 status and that AdoMet is able to inhibit the CRC proliferation with an efficacy comparable to that described in other types of human cancer cells [8,10]. Here, TP53 is linked to colorectal carcinoma.